Appearance of B220low autoantibody-producing B-1 cells at neonatal and older stages in mice

Tachikawa, Shinzo; Kawamura, Toshihiko; Kawamura, Hiroki; Kanda, Yasuhiro; Fujii, Y.; Matsumoto, Hiroaki; Abo, Toru

doi:10.1111/j.1365-2249.2008.03709.x

Cited by 15 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, at the onset of autoimmune disease in NZB/W F 1 mice 17 or in mice with chronic graft‐versus‐host disease, 18 NK1.1 − TCR int cells and autoantibody‐producing B‐1 cells are simultaneously activated in the liver. A similar phenomenon appears in mice with malarial infection 19,20 and in aging mice 21 …”

Section: Introductionsupporting

confidence: 59%

“…It is speculated that autoantibodies detected in sera might be derived from B‐1 cells in both the liver and peritoneal cavity. A restricted production of the autoantibodies from purified B220 low cells (B‐1 cells) was confirmed by sorting experiments 21,28 …”

Section: Discussionmentioning

confidence: 87%

“…Such diseases include autoimmune states in NZB/W F 1 autoimmune‐prone mice 17 and in mice with chronic graft‐versus‐host disease 18 . Autoimmune states occurred in physiological events, namely, with aging 21 . Aged mice show a high titre of autoantibodies in sera and the simultaneous activation of NK1.1 − TCR int cells and B‐1 cells.…”

Section: Discussionmentioning

confidence: 99%

“…A similar phenomenon appears in mice with malarial infection 19,20 and in aging mice. 21 In light of these findings, in this study we investigated whether the activation of NKT cells accompanied autoantibody production. As NKT cells are known to be activated by the administration of a-GalCer, [6][7][8][9] we applied this model for activation of NKT cells and report that the Summary Natural killer T (NKT) cells are known to be specifically activated by a-galactosylceramide (a-GalCer) via their interaction with CD1d.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Coincidence of autoantibody production with the activation of natural killer T cells in α‐galactosylceramide‐mediated hepatic injury

et al. 2011

View full text Add to dashboard Cite

Summary Natural killer T (NKT) cells are known to be specifically activated by α‐galactosylceramide (α‐GalCer) via their interaction with CD1d. At that time, NKT cells mediate autoreactivity and eventually induce hepatic injury. As these immune responses resemble acute autoimmune hepatitis, it was examined whether autoantibody production and the activation of autoantibody‐producing B‐1 cells were accompanied by this phenomenon. Autoantibodies against Hep‐2 cells and double‐stranded DNA were detected in sera as early as day 3 (showing a peak at day 14) when mice were treated with α‐GalCer. On day 3, B220low cells appeared in the liver. These B220low cells were CD5− (i.e. B‐1b cells) and CD69+ (an activation marker). Primarily, such B220low cells were present in the peritoneal cavity, but the proportion of B220low cells increased with the administration of α‐GalCer even at this site. In parallel with the appearance of B220low cells in the liver, hepatic lymphocytes acquired the potential to produce autoantibodies in in vitro cell culture in the presence of lipopolysaccharide. These results suggested that hepatic injury induced by α‐GalCer administration resembled acute autoimmune hepatitis and that the major effector lymphocytes were NKT cells with autoreactivity and autoantibody‐producing B‐1 cells.

show abstract

Section: Introductionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Coincidence of autoantibody production with the activation of natural killer T cells in α‐galactosylceramide‐mediated hepatic injury

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Autoantibodies are produced by B cells during physiological immune responses in elderly people and neonates. It is thought that they play a role in the elimination of denatured cells (19,20).…”

Section: Discussionmentioning

confidence: 99%

Treatment of Autoimmune Urticaria with Low-dose Cyclosporin A: A One-year Follow-up

Boubouka

Charissi²,

Kouimintzis³

et al. 2011

Acta Derm Venerol

View full text Add to dashboard Cite

Patients with autoimmune urticaria (AIU) and positive autologous serum skin test (ASST) represent a more serious type of chronic urticaria that does not respond to treatment with antihistamines, but responds completely to systemic corticosteroids. Because of the chronic course of the disease, there is a risk of side-effects. Cyclosporin A (CsA) is an alternative treatment for patients with AIU. In order to determine the efficacy of CsA at the lowest possible dose in patients with chronic idiopathic urticaria and positive ASST, 30 patients were included in a 5-month study with a follow-up one year after the end of treatment. All patients had positive ASST before treatment and autoantibodies were present in 73%. Twenty- three patients completed the study and responded to low-dose CsA treatment. Three patients did not respond to a dose of 2.5 mg/kg CsA, and 4 patients dropped-out due to side-effects. After the first month of treatment, an improvement of 31% was noted, reaching 88% after the fifth month of treatment. The mean dose of CsA was 2.16 mg/kg for the first month and 0.55 mg/kg for the fifth month. Three to 6 months after the end of the study, the ASST was repeated and was negative in 78.3% of patients. At the one-year follow-up, 20 patients were symptom-free (87%) and 3 had relapsed (13%). CsA, even in low-doses, can be an effective and short-term treat- ment with minimum side-effects in patients with AIU.

show abstract

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity

Cecil

Park

Gad

et al. 2013

Breast Cancer Res Treat

View full text Add to dashboard Cite

Numerous lines of evidence demonstrate that breast cancer is immunogenic; yet, there are few biologically relevant immune targets under investigation restricting the exploration of vaccines to limited breast cancer subtypes. Insulin-like growth factor-I receptor (IGF-IR) is a promising vaccine candidate since it is overexpressed in most breast cancer subtypes, is part of a dominant cancer growth pathway, and has been validated as a therapeutic target. We questioned whether IGF-IR was immunogenic in cancer patients. IGF-IR-specific IgG antibodies were significantly elevated in early-stage breast cancer patients at the time of diagnosis as compared to volunteer donors (p = 0.04). Predicted T-helper epitopes, derived from the IGF-IR extracellular and transmembrane domains, elicited a significantly higher incidence of Th2 immunity in breast cancer patients as compared to controls (p = 0.01). Moreover, the magnitude of Th2 immunity was greater in breast cancer patients compared to controls (p = 0.02). In contrast, both breast cancer patients and volunteer donors demonstrated a similar incidence of Th1 immunity to IGF-IR domains with the predominant response directed against epitopes in the intracellular domain of the protein. As the incidence of IGF-IR type I immunity was not associated with a breast cancer diagnosis, we questioned whether other factors were contributing to the presence of IGF-IR-specific T-cells in both populations. While age was not associated with Th1 immunity, we observed a significantly greater magnitude of IGF-IR IFN-γ-secreting T-cells in obese subjects as compared to overweight (p < 0.001) or healthy-weight (p = 0.006) subjects, regardless of breast cancer diagnosis. No significant difference was observed for Th2 incidence or magnitude when stratified by age (p = 0.174, p = 0.966, respectively) or body mass index (p = 0.137, p = 0.174, respectively). Our data demonstrate that IGF-IR is a tumor antigen and IGF-IR-specific Th1 immunity may be associated with obesity rather than malignancy.

show abstract

Appearance of B220low autoantibody-producing B-1 cells at neonatal and older stages in mice

Cited by 15 publications

References 25 publications

Coincidence of autoantibody production with the activation of natural killer T cells in α‐galactosylceramide‐mediated hepatic injury

Coincidence of autoantibody production with the activation of natural killer T cells in α‐galactosylceramide‐mediated hepatic injury

Treatment of Autoimmune Urticaria with Low-dose Cyclosporin A: A One-year Follow-up

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity

Contact Info

Product

Resources

About